Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the ...
In trading on Tuesday, shares of Novo-Nordisk AS (Symbol: NVO) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $81 per share. By comparison ...
Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. If we consider the specifics of ...
Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback